Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

Article  PubMed  Google Scholar 

Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, Lopez-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Ruschoff J (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18:476–484. https://doi.org/10.1007/s10120-014-0402-y

Article  CAS  PubMed  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697. https://doi.org/10.1016/S0140-6736(10)61121-X

Article  CAS  PubMed  Google Scholar 

Xiao H, Wang X, Li S, Liu Y, Cui Y, Deng X (2021) Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction. Front Cardiovasc Med 8:753313. https://doi.org/10.3389/fcvm.2021.753313

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wittrup A, Lieberman J (2015) Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet 16:543–552. https://doi.org/10.1038/nrg3978

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen J, Zhang W, Qi R, Mao ZW, Shen H (2018) Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics. Chem Soc Rev 47:1969–1995. https://doi.org/10.1039/c7cs00479f

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Xie Y, Kilchrist KV, Li J, Duvall CL, Oupicky D (2020) Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy. ACS Appl Mater Interfaces 12:4308–4322. https://doi.org/10.1021/acsami.9b21214

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maia J, Caja S, StranoMoraes MC, Couto N, Costa-Silva B (2018) Exosome-Based Cell-Cell Communication in the Tumor Microenvironment. Front Cell Dev Biol 6:18. https://doi.org/10.3389/fcell.2018.00018

Article  PubMed  PubMed Central  Google Scholar 

Wang X, Zhou Y and Ding K (2021) Roles of exosomes in cancer chemotherapy resistance, progression, metastasis and immunity, and their clinical applications (Review). Int J Oncol 59. https://doi.org/10.3892/ijo.2021.5224

Thery C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2:569–579. https://doi.org/10.1038/nri855

Article  CAS  PubMed  Google Scholar 

Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H (2018) New Technologies for Analysis of Extracellular Vesicles. Chem Rev 118:1917–1950. https://doi.org/10.1021/acs.chemrev.7b00534

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, Wei J, Nie G (2014) A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35:2383–2390. https://doi.org/10.1016/j.biomaterials.2013.11.083

Article  CAS  PubMed  Google Scholar 

Bang C, Thum T (2012) Exosomes: new players in cell-cell communication. Int J Biochem Cell Biol 44:2060–2064. https://doi.org/10.1016/j.biocel.2012.08.007

Article  CAS  PubMed  Google Scholar 

Lin D, Zhang H, Liu R, Deng T, Ning T, Bai M, Yang Y, Zhu K, Wang J, Duan J, Ge S, Sun B, Ying G, Ba Y (2021) iRGD-modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation. Mol Oncol 15:3430–3446. https://doi.org/10.1002/1878-0261.13052

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu KG, Yang J, Zhu Y, Zhu Q, Pan W, Deng S, He Y, Zuo D, Wang P, Han Y, Zhang HY (2023) The microprotein encoded by exosomal lncAKR1C2 promotes gastric cancer lymph node metastasis by regulating fatty acid metabolism. Cell Death Dis 14:708. https://doi.org/10.1038/s41419-023-06220-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao Y, Jiang Y, Song J, Wang R, Li Z, Yang L, Wu W, Zhang L, Peng Q (2023) Exosomes as Potential Functional Nanomaterials for Tissue Engineering. Adv Healthc Mater 12:e2201989. https://doi.org/10.1002/adhm.202201989

Article  CAS  PubMed  Google Scholar 

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E (2010) Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328:1031–1035. https://doi.org/10.1126/science.1183057

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun L, Zhang J, Xu M, Zhang L, Tang Q, Chen J, Gong M, Sun S, Ge H, Wang S, Liang X, Cui L (2022) Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer. ACS Appl Mater Interfaces 14:452–463. https://doi.org/10.1021/acsami.1c21924

Article  CAS  PubMed  Google Scholar 

Ait-Si-Ali S, Guasconi V, Harel-Bellan A (2004) RNA interference and its possible use in cancer therapy. Bull Cancer 91:15–18

CAS  PubMed  Google Scholar 

Roberts TC, Ezzat K, El Andaloussi S, Weinberg MS (2016) Synthetic SiRNA Delivery: Progress and Prospects. Methods Mol Biol 1364:291–310. https://doi.org/10.1007/978-1-4939-3112-5_23

Article  CAS  PubMed  Google Scholar 

Bobbin ML, Rossi JJ (2016) RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? Annu Rev Pharmacol Toxicol 56:103–122. https://doi.org/10.1146/annurev-pharmtox-010715-103633

Article  CAS  PubMed  Google Scholar 

Kim HJ, Kim A, Miyata K, Kataoka K (2016) Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Deliv Rev 104:61–77. https://doi.org/10.1016/j.addr.2016.06.011

Article  CAS  PubMed  Google Scholar 

Liang Y, Duan L, Lu J, Xia J (2021) Engineering exosomes for targeted drug delivery. Theranostics 11:3183–3195. https://doi.org/10.7150/thno.52570

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R (2017) Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546:498–503. https://doi.org/10.1038/nature22341

Du L, Gong Y, Zhang X, Sun J, Gao F, Shen M, Bai H, Yang T, Cheng X, Li S, Peng J, Liu Z, Ding S, Chen J, Cheng W (2024) PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy. J Nanobiotechnology 22:(1)442. https://doi.org/10.1186/s12951-024-02700-4

Gondaliya P, Sayyed AA, Yan IK, Driscoll J, Ziemer A, Patel T (2024) Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy. Mol Ther 32:2762–2777. https://doi.org/10.1016/j.ymthe.2024.06.006

Zhang Q, Zhang H, Ning T, Liu D, Deng T, Liu R, Bai M, Zhu K, Li J, Fan Q, Ying G, Ba Y (2022) Exosome-Delivered c-Met siRNA Could Reverse Chemoresistance to Cisplatin in Gastric Cancer [Corrigendum]. International Journal of Nanomedicine Volume 17:1003–1004. https://doi.org/10.2147/IJN.S362734

Article  Google Scholar 

Wang C, Li N, Li Y, Hou S, Zhang W, Meng Z, Wang S, Jia Q, Tan J, Wang R, Zhang R (2022) Engineering a HEK-293T exosome-based delivery platform for efficient tumor-targeting chemotherapy/internal irradiation combination therapy. J Nanobiotechnology 20:247. https://doi.org/10.1186/s12951-022-01462-1